New patent granted for non-cancer applications
Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- PharmAust secures core China patent
- Appendix 4C - Quarterly Report & Company Update - March 2017
- Dr Richard Hopkins Appointed as CEO of PharmAust
- Appendix 4D & Financial Report - Dec 2016
- Appendix 4C - Quarterly Report & Company Update
Later from Neurizon Therapeutics
- Phase II trial prelim results demonstrate clinical benefit
- PharmAust secures core patent in Japan
- New European patent granted for non-cancer applications
- Canadian-based specialists to reformulate monepantel
- Epichem reports record $3m revenues & expands laboratory
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics